Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV‐IG prophylaxis: A monocentric retrospective analysis
- 12 February 2021
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (11), 6292-6300
- https://doi.org/10.1002/jmv.26861
Abstract
Human cytomegalovirus (CMV) represents the most common viral infection after hematopoietic stem cell transplant (HSCT), mainly occurring as reactivation from latency in seropositive patients, with a different prevalence based on the extent and timing of seroconversion in a specific population. Here, we retrospectively analyzed a cohort of patients who underwent HSCT at our Institution between 2013 and 2018, all of whom were prophylactically treated with CMV‐IG (Megalotect Biotest®), to define the incidence and clinical outcomes of CMV reactivation and clinically significant infection. CMV infection occurred in 69% of our patient series, mainly resulting from reactivation, and CMV clinically significant infection (CS‐CMVi) occurred in 48% of prophylactically treated patients. CMV infection and CS‐CMVi impacted neither on relapse incidence nor on overall survival nor on relapse‐free survival. Moreover, a very low incidence of CMV end‐organ disease was documented. CMV‐IG used alone as prophylactic therapy after HSCT does not effectively prevent CMV reactivation.Keywords
This publication has 42 references indexed in Scilit:
- The pathogenesis of human cytomegalovirusThe Journal of Pathology, 2014
- Donor Cytomegalovirus Status Influences the Outcome of Allogeneic Stem Cell Transplant: A Study by the European Group for Blood and Marrow TransplantationClinical Infectious Diseases, 2014
- Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell TransplantationThe New England Journal of Medicine, 2014
- Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO)Transplantation and Cellular Therapy, 2014
- CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMTBlood, 2013
- CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemiaBlood, 2013
- Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patientsBlood, 2011
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Circulating Cytomegalovirus (CMV)-Infected Endothelial Cells in Patients with an Active CMV InfectionThe Journal of Infectious Diseases, 1993